----
Current ValuationThe current P/E ratio is -31.74, below the reasonable range, cheaper than 91.15% of the time in the past 1 years, and the industry ranks 148/173, the industry Median -0.80.
-31.74xP/E
$6.37Stock price
$-0.20Earnings per share
-31.74xP/E
Stock price$6.37Earnings per share$-0.20
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -15.78x
- Typical range
- -28.32x–-12.06x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
014284256
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -18.45x | 166.27% | $13.34B |
GKOSUSGlaukos | -77.95x | 90.98% | $13.24B |
PLSEUSPulse Biosciences | -46.81x | 21.30% | $3.92B |
IRTCUSIRhythm | -77.07x | 16.40% | $2.97B |
AXGNUSAxogen | -91.94x | 12.42% | $2.93B |
ASSTUSStrive | -9.05x | 57.99% | $2.66B |
BFLYUSButterfly Network | -31.74x | 36.13% | $1.70B |
KMTSUSKestra Medical Tech | -11.26x | 0.79% | $1.69B |
ENOVUSEnovis | -2.97x | 99.13% | $1.57B |
NVCRUSNovocure | -12.75x | 13.66% | $1.55B |
DRTSUSAlpha Tau Medical | -13.68x | -- | $1.27B |
PRCTUSPROCEPT BioRobotics | -10.33x | 1.23% | $1.19B |
TNDMUSTandem Diabetes | -23.97x | 80.88% | $1.18B |
ATECUSAlphatec | -13.28x | 51.67% | $1.15B |
SIBNUSSI-BONE | -79.90x | 21.94% | $1.09B |
CBLLUSCeribell | -13.98x | 39.46% | $1.03B |
AORTUSArtivion | -55.91x | 326.99% | $986.04M |
BBNXUSBeta Bionics | -10.27x | 13.23% | $853.56M |
QDELUSQuidelOrtho | -1.99x | 72.55% | $734.15M |
SGHTUSSight Sciences | -19.73x | 27.70% | $560.24M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
